2 years ago
CBAY
AnalystsSean KimSean Kim's Stock Forecasts
AnalystsSean Kim
Sectors:
Analyst Ranking
Bottom 17%
#4056 out of 4871 analysts
Average Return
-7.77%
Win Rate
40%4 out of 10
Risk vs Reward
Poor
Good
Sean Kim's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Cymabay Therapeutics IncCBAY | +152.76% | $12.85 | $32.48 | 2023-08-14 - 2024-03-21 | Strong Buy |
Trevi Therapeutics IncTRVI | +61.41% | $1.84 | $2.97 | 2023-03-13 - 2024-03-13 | Strong Buy |
Eyepoint Pharmaceuticals IncEYPT | +32.15% | $7.03 | $9.29 | 2023-06-13 - 2024-06-13 | Strong Buy |
Concert Pharmaceuticals IncCNCE | +21.66% | $6.88 | $8.37 | 2022-08-24 - 2023-03-03 | Strong Buy |
Sean Kim Analyst Color
Get additional color on Sean Kim's coverage of popular stocks
Sean Kim's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Cymabay Therapeutics IncCBAY | 1 | Strong Buy | $15.00 | N/A | Maintains | 2 years ago |
Clearside Biomedical IncCLSD | 1 | Strong Buy | $6.00 | N/A | Initiates Coverage On | 2 years ago |
Ovid Therapeutics IncOVID | 1 | Strong Buy | $6.00 | N/A | Initiates Coverage On | 2 years ago |
Eyepoint Pharmaceuticals IncEYPT | 1 | Strong Buy | $26.00 | N/A | Initiates Coverage On | 2 years ago |
Trevi Therapeutics IncTRVI | 1 | Strong Buy | $7.00 | N/A | Initiates Coverage On | 2 years ago |
Durect CorpDRRX | 1 | Strong Buy | $37.00 | N/A | Initiates Coverage On | 2 years ago |
Arcutis Biotherapeutics IncARQT | 1 | Strong Buy | $54.00 | N/A | Assumes | 3 years ago |
Satsuma Pharmaceuticals IncSTSA | 1 | Strong Buy | $14.00 | N/A | Initiates Coverage On | 3 years ago |
Impel Pharmaceuticals IncIMPLQ | 1 | Strong Buy | $26.00 | N/A | Initiates Coverage On | 3 years ago |
Concert Pharmaceuticals IncCNCE | 1 | Strong Buy | $17.00 | N/A | Initiates Coverage On | 3 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.